GILD Archives - Page 28 of 29

1 minute read

Earnings

Gilead Sciences: Q2 Earnings Insights

August 2, 4:42 PM

Gilead Sciences (NASDAQ:GILD) reported its Q2 earnings results on Tuesday, August 2, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings Gilead Sciences beat estimated earnings by 3.27%, reporting an EPS of $1.58 versus an estimate of $1.53.

GILD

1 minute read

Gilead Sciences Q2 EPS $1.58 Beats $1.53 Estimate

By Benzinga Newsdesk

August 2, 4:04 PM

Gilead Sciences (NASDAQ:GILD) reported quarterly earnings of $1.58 per share which beat the analyst consensus estimate of $1.53 by 3.27 percent. This is a 15.51 percent decrease over earnings of $1.87 per share from the

GILD

17 minute read

Earnings Scheduled For August 2, 2022

By Benzinga Insights

August 2, 4:37 AM

Companies Reporting Before The Bell • Ferrari (NYSE:RACE) is expected to report quarterly earnings at $1.27 per share on revenue of $1.22 billion.

ABNB

3 minute read

Recap Of Thursday’s Biotech Catalysts – End of The Day Summary

By Ragothaman Srinivasan

July 28, 6:38 PM

Cyclerion Therapeutics (NASDAQ:CYCN) announced positive topline data from its clinical study of CY6463 for the treatment of Cognitive…

ACER

1 minute read

Gilead’s Biktarvy Demonstrates High Efficacy In HIV/HBV Coinfection Patients

By Vandana Singh

July 28, 3:09 PM

Gilead Sciences Inc (NASDAQ:GILD) announced results reinforcing Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) as a highly efficacious treatment option for HIV, including individuals with…

GILD

2 minute read

Recap Of Friday’s Biotech Catalysts – End Of The Day Summary

By Ragothaman Srinivasan

July 22, 5:59 PM

Bristol Myers Squibb (NYSE:BMY) received European Medicines Agency (EMA) Positive CHMP Opinion recommending approval for Opdualag (nivolumab and…

BMY

1 minute read

European Commission Signs COVID-19 Drug Procurement Deal With Gilead

By Vandana Singh

July 19, 12:30 PM

Gilead Sciences Inc (NASDAQ:GILD) and the European Commission signed a joint procurement agreement for rapid and equitable access to the COVID-19…

GILD

1 minute read

Morgan Stanley Maintains Equal-Weight on Gilead Sciences, Raises Price Target to $65

By Benzinga Newsdesk

July 15, 10:46 AM

Morgan Stanley analyst Matthew Harrison maintains Gilead Sciences (NASDAQ:GILD) with a Equal-Weight and raises the price target from $63 to $65.

GILD

2 minute read

Gilead Sciences Whale Trades For July 14

By Benzinga Insights

July 14, 4:55 PM

Someone with a lot of money to spend has taken a bearish stance on Gilead Sciences (NASDAQ:GILD). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

GILD

4 minute read

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

July 14, 1:50 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

ABT

Feed Symbols: GILD